ad

Corona Remedies IPO GMP & Review: Apply or Avoid?

Posted by : sachet | Thu Dec 04 2025

Corona Remedies IPO GMP & Review: Apply or Avoid?

Corona Remedies IPO is open for bidding from 8th December 2025 to 10th December 2025. It is a bookbuilding IPO of ₹655.37 crore, an entirely offer-for-sale of 0.62 shares. The issue will be listed on BSE and NSE on its tentative listing date, 15th December 2025. 

Corona Remedies IPO Details 

The Corona Remedies IPO date is fixed between 8th December 2025 and 10th December 2025. The face value of Corona Remedies shares stands at ₹10 per share, and the IPO Issue price band is set at ₹1,008 to ₹1062 per share

Bigshare Services Private Limited is the registrar of the Corona Remedies IPO and is responsible for managing the allotment process and initiating refunds. Check out the latest IPO details in the table below. 

IPO Allotment Date11th December 2025
IPO Open Date8th December 2025
IPO Close Date10th December 2025
Refund Initiation 12th December 2025
Issue Size61,71,101 shares(aggregating up to ₹655.37 Cr)
Face Value₹10 per share
Lot Size14 Shares
Issue Price ₹1,008 to ₹1,062 per share
Issue TypeBookbuilding IPO
Listing AtBSE NSE
Listing Date15th December 2025

Corona Remedies IPO Share Reservation

Corona Remedies IPO is a bookbuilding IPO issue of worth ₹655.37 crores. Corona Remedies IPO Limited shares will be listed on the BSE and the NSE Exchange. Furthermore, SEBI has specified the share reservation criteria for different investor categories. 

Investor CategoriesShares Offered 
QIB shares offeredNot more than 50% of the Net Offer
NII (HNI) Shares OfferedNot less than 15% of the Net Offer
Retail Shares OfferedNot less than 35% of the Net Offer

Corona Remedies IPO GMP Grey Market Premium

GMP is the gap between the price band of the issue and the price at which company shares are currently trading in the grey market. Do you want to get live updates on the Corona Remedies IPO? If yes, then you’ve reached the right spot. Check the table below to learn about the GMP trends.

GMP DATEIPO PriceGMP PriceEstimated Listing PriceEstimated Gain
10-12-2025––––
9-12-2025––––
8-12-2025₹1,062.00₹330.00₹1,392.0031.07%
7-12-2025₹1,062.00₹330.00₹1,392.0031.07%
6-12-2025₹1,062.00₹330.00₹1,392.0031.07%
5-12-2025₹1,062.00₹330.00₹1,392.0031.07%
4-12-2025₹1,062.00₹330.00₹1,392.0031.07%
3-12-2025₹1,062.00₹0.00₹1,062.000.00%
2-12-2025₹1,062.00₹0.00₹1,062.000.00%

As of 5th December 2025, Corona Remedies IPO GMP stands at ₹330 per share, which means the share will likely show a listing at ₹1,392.00 on its tentative listing date, 15th December 2025.

GMP data is subject to change based on market trends and sentiments. You should check the live GMP status before applying for the Corona Remedies IPO GMP. Stay informed with Univest for real-time insights into IPOs and their GMP trends. 

Corona Remedies IPO GMP Review

Check out the detailed Corona Remedies GMP IPO review for a thorough understanding of its potential to report listing gains on 15th December 2025. The Corona Remedies IPO review below will help you invest effectively to avoid significant losses. Explore more to make informed investment decisions on this IPO. 

Financial Health

Assess a company’s financial performance to know about its ability to sustain a competitive edge. Thus, it is essential to understand the business’s economic growth and decline before applying for the Corona Remedies IPO.

Corona Remedies Limited’s revenue soared by 18% from ₹1,020.93 crores in March 2024  to ₹1,202.35 crores in March 2025. Moreover, the company’s PAT increased by 65% from ₹90.50 crores in March 2024 to ₹149.43 crores in March 2025.

Corona Remedies’ IPO has shown consistent revenue growth, indicating the company’s financial stability. Moreover, the brokers, investors, and RAs have a positive outlook for the Corona Remedies IPO for its tentative listing day, which is 15th December 2025. 

Technical Analysis

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technicals of the Corona Remedies IPO.

Key IndicatorsValue
PE Ratio (Price-to-Earnings) 43.47
EPS (Earnings Per Share)24.23
RoNW24.65%
ROCE41.32%
ROE27.50%
EBITDA Margin20.55%
Price to Book Value10.71
Market Capitalisation₹6,495.20

The PE ratio of Corona Remedies Limited shares is 43.47, and its Earnings Per Share (EPS) stands at 24.43. Thus, the Corona Remedies IPO can deliver gains on its tentative listing date, 12th December 2025. 

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Corona Remedies Limited are subject to change after the IPO. Explore the table below to get post-issue updates on these two metrics. 

IndicatorsPre-IPOPost-IPO
PE Ratio43.4735.15
EPS 24.4330.21

Corona Remedies IPO Subscription Status

The Corona Remedies IPO is to be opened for bidding on 8th December 2025. The subscription status for this IPO is yet to be announced. Stay informed on this passage to check the live Corona Remedies IPO Subscription Status. 

Investor CategoryShares OfferedShares SubscribedSubscription to the Times
QIB shares offeredNot more than 50% of the Net OfferYet to be announcedYet to be announced
NII (HNI) Shares OfferedNot less than 15% of the Net OfferYet to be announcedYet to be announced
Retail Shares OfferedNot less than 35% of the Net OfferYet to be announcedYet to be announced

About Corona Remedies Limited

Corona Remedies was established in August 2004. Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas. As of June 30, 2025, the company’s diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory). The company has a pan-India marketing and distribution network with 2,671 medical representatives across 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM, and ensuring deep penetration across therapeutic areas.

Corona Remedies Limited Financials

The company’s financial analysis is essential before applying for the Corona Remedies IPO. Look at the table to learn about Corona Remedies Limited’s financials. 

Year Ended30th June 2025 (in cr.)31st March 2025 (in cr.)31st March 2024
Assets1,012.38929.86830.58
Revenue348.561,202.351,020.93
Profit After Tax46.20149.4390.50
EBITDA71.80245.91161.19
Net Worth607.02606.34480.41
Reserves and Surplus545.86545.18419.25
Total Borrowings106.6562.70134.14

Explanation

Corona Remedies Limited’s revenue soared by 18% from ₹1,020.93 crores in March 2024  to ₹1,202.35 crores in March 2025. Moreover, the company’s PAT increased by 65% from ₹90.50 crores in March 2024 to ₹149.43 crores in March 2025.

Corona Remedies Limited IPO Promoter Holdings

Have a look at the table below to check the holdings of Corona Remedies Limited.

Mr Hitesh Kumar Singla, Mr Nikhil Singla, Mr Nitin Dixit, and Mr Anil Kumar Sharma.

Shareholding Pre-Issue72.50%
Shareholding Post-Issue–

Note: The value will be calculated using Equity Dilution = Share Holding Pre Issue – Share Holding Post Issue.

Aim of Corona Remedies IPO

The primary aim of the Corona Remedies IPO is to raise ₹655.37 crores. On the other hand, Corona Remedies has decided to utilise these funds in different ways.

Should I Invest in the Corona Remedies IPO?

Explore the pros and cons of Corona Remedies to know whether you should apply or avoid the issue. These pros and cons might help you understand the IPO’s efficiency in delivering profits over the coming decades. 

Pros of Corona Remedies IPO

  • The company is the second-fastest-growing among the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to seize opportunities in the Indian market.
  • The Comonay demonstrated the capability to build a diversified portfolio, including “engine” brands, in our targeted therapy areas.
  • The company has a qualified, experienced and entrepreneurial management team supported by marquee investors.

Cons of Corona Remedies IPO

  • The company has a revenue & business concentration risk
  • The company has a heavy dependence on a few products and brands 
  • The company has domestic market dependence.
  • The company has depended on the supply chain and the supplier.

How to Apply for Corona Remedies IPO?

Check the steps mentioned below to apply for Corona Remedies Ltd.

  • Step 1: Conduct thorough research on the Corona Remedies IPO GMP, subscription status, issue size, lot size, and other details. 
  • Step 2: Open a demat account with Univest to access real-time insights on GMP and subscription status. You can also use your previous demat account by navigating to the IPO section. 
  • Step 3: You will receive a mandate request after making a bid. Approve the request to proceed further.    

Note: You can apply for the Corona Remedies IPO across multiple demat accounts to increase your chances of allotment. 

How to Check Corona Remedies IPO Allotment Status?

You can check for the Corona Remedies IPO allotment in different ways. These include NSE and the registrar portal. Follow the steps below to check your allotment status online.

Check On NSE

  • Visit the NSE Official Site
  • Navigate to the IPO Allotment Section. 
  • Select Equity as the issue type. 
  • Choose the Corona Remedies IPO.  
  • Choose whether to proceed with the PAN number or the application number.
  • Submit your details to get the allotment status online. 

Check On the Registrar Portal

  • Visit the registrar portal.
  • Click on the allotment option.
  • Fill in the required details.
  • Click on the submit button to know your Corona Remedies IPO allotment status.

Let’s Wrap

Corona Remedies IPO is a bookbuilding issue of shares worth ₹655.37 crores. The shares of Corona Remedies Limited will be listed on NSE and SME on its tentative listing date of 15th December 2025. Researching the Corona Remedies IPO GMP and reviews is highly suggested to book your ideal profitability. Brokers and investors have highlighted their pros and cons, so one must analyse them and decide accordingly.

Open a demat account on Univest now to initiate your investment journey!

FAQs on Corona Remedies IPO

How is the Corona Remedies IPO?

Ans. Currently, on 8th December 2025, the Corona Remedies GMP (Grey Market Premium) stands at ₹330. It indicates that the estimated listing price could be ₹1,392.00 per share. It is a bookbuilding IPO of ₹655.37 shares. The face value of each Corona Remedies share is ₹10. 

What is the Corona Remedies IPO price?

Ans. The Corona Remedies IPO issue price band is set at ₹1,008.00 to ₹1,062.00 per share. 

Is the Corona Remedies IPO a good investment?

Ans. Corona Remedies Limited’s revenue soared by 18% from ₹1,020.93 crores in March 2024  to ₹1,202.35 crores in March 2025. Moreover, the company’s PAT increased by 65% from ₹90.50 crores in March 2024 to ₹149.43 crores in March 2025.

Who is the registrar of the Corona Remedies IPO?

Ans.  Bigshare Services Private Limited is the registrar for the Corona Remedies IPO, awaiting to manage the allotment process and initiate refunds. For any queries regarding the Corona Remedies allotment and refund, you can contact Bigshare Services Private Limited at ipo@bigshareonline.com or +91-22-6263 8200.

What is the issue size of the Corona Remedies IPO? 

Ans. Corona Remedies IPO is a bookbuilding IPO for ₹655.37 shares. Moreover, the IPO is set to open on 8th December 2025 and will be closed on 10th December 2025. 

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Corona Remedies IPO, download the Corona Remedies IPO RHP and Corona Remedies IPO DRHP. Conduct your research before investing in IPOs to avoid significant losses. You can also consult your financial advisor.

Upcoming IPOs

IPO NamesExpected Year of IPO
PhonePe IPO2025
Bajaj Energy IPO2025
OYO IPO2025
NSDL IPO2025
Flipkart IPO2025
Zepto IPO2025
Boat IPO2025
Meesho IPO2025
Jio IPO2026
NSE IPO2025

Current & Previous IPOs

CompanyIPO OpenIPO CloseType
Anthem Biosciences Limited14th July 202516th July 2025Mainboard
Spunweb Nonwoven Limited14th July 202516th July 2025SME
Smartworks Coworking Spaces Limited10th July 202514th July 2025Mainboard
CFF Fluid Control Limited9th July 202511th July 2025SME
GLEN Industries Limited8th July 202510th July 2025SME
Chemkart India Limited7th July 20259th July 2025SME
Travel Food Services Limited7th July 20259th July 2025Mainboard
Smarten Power Systems Limited7th July 20259th July 2025SME
Meta Infotech Limited4th July 20258th July 2025SME
Cryogenic OGS Limited3rd July 20257th July 2025SME
Happy Square Outsourcing Services Limited3rd July 20257th July 2025SME
Crizac Limited3rd July 20257th July 2025Mainboard
Silky Overseas Limited30th June 20252nd July 2025SME
Pushpa Jewellers Limited30th June 20252nd July 2025SME
Cedaar Textile Limited30th June 20252nd July 2025SME
Marc Loire Fashions Limited30th June 20252nd July 2025SME

Read Our Articles on the Best Stocks

Tech Stocks in India to Invest in 2025 | Tech Sector Stocks 

Best Battery Stocks in India to Invest in 2025 | Battery Sector Stocks 

Best Shipping Stocks in India to Invest in 2025 | Shipping Sector Stocks 

Paint Stocks in India to Invest in 2025 | Paint Sector Stocks 

Paper Stocks in India to Invest in 2025 | Paper Sector Stocks 

Best Semiconductor Stocks in India 2025 

Best Large Cap Stocks in India 2025 

Green Energy Penny Stocks

Best Cement Stocks To Invest In India

Also Explore

Best Stocks Multibagger Stocks Penny StocksFundamentally Strong Stocks Sector-Wise StocksPSU /Government Stocks
For the Next 10 YearsFor the Next 5 YearsSolar Penny StocksOn BSESolar Energy SectorPSU Stocks List
Long Term Below 100 RsTop 5 Penny StocksFor Long-TermHospitality Sector PSU Stocks in 20Rs
Best Bike StocksFor 2025Best Penny Stocks in IndiaPenny SharesHotel SectorGovernment Stocks in 2024
Best Liquor StocksHigh-Growth StocksFor 2025Agriculture SectorGovernment Stocks List
Best Railway StocksUnder 500Penny Stocks Pharma SectorGovernment Stocks in 2025
Best Auto StocksFor 2026Oil and Gas Sector

Univest Screeners

ExclusiveIndicesBreakouts
Buy in the Short TermNifty Small Cap 100Daily Fresh Breakouts
Buy in the Long TermNifty MidcapWeekly Breakouts
FII Holdings ChangeNifty BankOversold Stocks
Golden CrossoverSensexNearing Breakout
Upcoming DividendsNifty Fin Service
DII Holdings ChangeBankex
High Dividend StocksNifty Mid Cap 100
Earnings AnnouncedNifty 50
Fundamentally Strong 
Top Gainers
Top Losers
Low Debt Mid Caps
Cash-Rich Small Caps
Volume Shockers
52-Week High 
52-Week Low

Explore Webstories on Univest 

Best Time To Buy Dividend Stocks

How RBI Policies Affect Dividend Stocks

Can Dividend Stocks Beat Inflation

What Is The Dividend Aristocrat List

Which Indian Psus Offer The Best Dividends

Large Cap Vs Small Cap Dividend Stocks

Related Posts

Western Overseas Study Abroad IPO Subscription Day 1

Western Overseas Study Abroad IPO GMP: Day 1 IPO Live Updates

Luxury Time IPO Subscription Day 1

Luxury Time IPO GMP: Day 1 IPO Live Updates

ad
icon

100% Safe & Secure Platform.

Univest encrypts all data and transactions to ensure a completely secure experience for our members.

Copyright

2025 Univest. All rights reserved. | Designed with ❤️ in India
About Univest
About: Univest is a cutting-edge stock market platform designed to help traders and investors maximize their returns with expert-driven advisory services and seamless trading execution. Whether you're a seasoned trader or just starting, Univest simplifies your investment journey with actionable trade recommendations, AI-powered portfolio insights, and a fully integrated brokerage experience. With Univest, you gain access to proven stock market advisory, offering expert trade ideas for stocks, futures, options, and commodities. Our one-click trade execution feature eliminates slippage, ensuring instant execution through our advisory-first brokerage. Smart portfolio management allows you to identify underperforming stocks, optimize your investments, and receive real-time alerts. Additionally, Univest provides seamless investment opportunities beyond stocks, including mutual funds, bonds, fixed deposits, and insurance (coming soon). Join over 40 lakh active investors who trust Univest to make informed and profitable trading decisions. Start investing smarter today! 🚀  
Attention Investors : To ensure a smooth trading experience and prevent unauthorized transactions, investors must update their mobile number and email ID with their stockbroker or depository participant. As per regulatory requirements, investors are required to pay a stipulated amount as an upfront margin for trading in the Cash/FO segment. We encourage all investors to regularly check their securities in the Consolidated Account Statement (CAS) issued by depository to verify their holdings.Always verify alerts and transaction details received directly from the exchange or NSDL before proceeding with any trades. Please do not make payments through unverified email links, WhatsApp, or SMS. Always trade through a registered stockbroker and verify all details before making financial decisions.
 
Disclaimer: Investments in the securities market are subject to market risks. Please read all related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. For more disclaimer /disclosure, visit https://univest.in/stock-broker or Univest App.We collect and use your contact information for legitimate business purposes, including providing updates on our products and services. We do not sell or rent your contact information to third parties. By submitting your details, you authorize us to contact you via Call/SMS, even if you are registered under DND. This authorization remains valid for 12 months.For grievances, please contact us at hello@unibrokers.in .
 
Univest Stock Broking Disclosures
Univest Stock Broking Private Limited - SEBI Reg. No. INZ000317437 (Stock Broker), NSE TM Code: 90392, BSE TM Code: 6866, MCX TM Code: 57290 and ICCL- Self Clearing Member Code: 6866, SEBI Reg. No. IN-DP-779-2024 (Participant), NSDL DP ID: IN304748.
 Risk Disclosures on Derivatives
1. 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
2. On an average, loss makers registered net trading loss close to ₹ 50,000
3. Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
4. Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Attention Investors: As per NSE circular dated July 6, 2022: https://nsearchives.nseindia.com/content/circulars/INSP52900.pdf, BSE circular dated July 6, 2022: https://www.bseindia.com/markets/MarketInfo/DispNewNoticesCirculars.aspx?page=20220706-55, MCX circular dated July 11, 2022: https://www.mcxindia.com/docs/default-source/circulars/english/2022/july/circular-418-2022.pdf?sfvrsn=9401991_0, investors are cautioned to abstain them from dealing in any schemes of unauthorised collective investments/portfolio management, indicative/ guaranteed/fixed returns / payments etc. 
Investors are further cautioned to avoid practices like:
a. Sharing 
i) trading credentials – login id and passwords including OTPs.
ii) trading strategies,
iii) position details.
b. Trading in leveraged products /derivatives like Options without proper understanding, which could lead to losses.
c. Writing/ selling options or trading in option strategies based on tips, without basic knowledge and understanding of the product and its risks.
d. Dealing in unsolicited tips through platforms like Whatsapp, Telegram, Instagram, YouTube, Facebook, SMS, calls, etc.
e. Trading / Trading in “Options” based on recommendations from unauthorised / unregistered investment advisors and influencers.
 Kindly read the Advisory Guidelines For Investors as prescribed by the Exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client’s assets: https://nsearchives.nseindia.com/content/circulars/INSP49434.pdf
Kindly, read the advisory as prescribed by the Exchange with reference to their circular: NSE/ISC/51035 dated January 14, 2022 regarding Updation of mandatory KYC fields by March 31, 2022: https://www.nseindia.com/resources/exchange-communication-circulars# 
Attention Investors: Prevent unauthorised transactions in your Demat account by updating your mobile number with your depository participant. Receive alerts on your registered mobile number for debit and other important transactions in your Demat account directly from NSDL on the same day. Prevent unauthorised transactions in your Trading account by updating your mobile numbers/email addresses with your stock brokers. Receive information on your transactions directly from the Exchange on your mobile/email at the end of the day. Issued in the interest of investors. KYC is a one-time exercise while dealing in securities markets - once KYC is done through a SEBI-registered intermediary (Broker, DP), you need not undergo the same process again when you approach another intermediary. As a business, we don’t give stock tips and have not authorised anyone to trade on behalf of others. If you find anyone claiming to be part of Univest Stock Broking Private Limited and offering such services, please send us an email at hello@unibrokers.in
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account.
Update your email ID and mobile number with your stockbroker/depository participant and receive an OTP directly from the depository on your registered email ID and/or mobile number. Check your securities/mutual funds/bonds in the Consolidated Account Statement (CAS) issued by NSDL every month.
Attention Investors: SEBI has established an Online Dispute Resolution Portal (ODR Portal) for resolving disputes in the Indian Securities Market. This circular streamlines the existing dispute resolution mechanism, offering online conciliation and arbitration, benefiting investors and listed companies https://www.sebi.gov.in/legal/circulars/jul-2023/online-resolution-of-disputes-in-the- indian-securities-market_74794.html. ODR portal for Investors - https://smartodr.in/login.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.
Quick Links: SEBI | NSE | BSE | MCX | Account Opening Process | Policies and Procedures | Register and Track Complaint | SEBI scores | SMART ODR | NSDL e-Voting | USCNBA | Account Closure | ContactUs 
Market Indices: Nifty 50 | Nifty 100 | Sensex | Nifty PSU Bank | Nifty Auto | Nifty 200 | Nifty 500 | Nifty Alpha 50 | Nifty Commodities | Nifty Consumptions | Nifty CPSE | Nifty Div Opps 50 | Nifty Energy | Nifty Growsect 15 | Nifty High Beta 50 | Nifty Fin Services | Nifty Infra | Nifty IT | Nifty Largemid 200 | NIfty Low Volatility 50 | Nifty Mid Cap 100
Screeners: Top Gainers | Top Losers | 52 Week High | 52 Week Low | FIIs Holding Change | DIIs Holding Change | Fundamentally Strong | Upcoming Dividends | Daily Fresh Breakout | Weekly Breakout | Nearing Breakout | Oversold Stocks | Volume Shockers | Golden Crossover | Short Term | Long Term | Top Stocks Result to Watch | Share Market Today
Sharks: Rakesh Jhunjhunwala | Radhakishan Damani | Azim Premji | Mukul Agrawal | Ashish Dhawan | Ashish kacholia | Anil Goel | Bhavook Tripathi | Vijay Kishanlal kedia  | Enam Securities | Vistra ITCL | Punjab National Bank | The Oriental Insurance Company | Jm Financial | GOVT. Of Singapore | EuroPacific Growth Fund | Govt. Pension Fund GLobal
Trending Stocks: ONGC | Zomato | Adani Enterprises | Reliance Industries | IOCL | Bajaj Auto |  Tata Motors | IRFC | IRCTC | Jindal Steel | HUDCO | BHEL | BEL | SBI | Kotak Bank | HDFC | Airtel | Coal India | LIC | Amber Enterprises | Kalyan Jewellers | Titan | JIO Fin Services | TCS | Infosys | Tech Mahindra | HCL | DLF | Godrej | ITC | Hindustan Unilever | NTPC | Power Finance Corp | Deepak Nitrite | Pidilite | Hero Moto Corp | ATUL | Maruti Suzuki | IndusInd Bank | CDSL | Indigo | L&T | RVNL | Grasim | MRF | CEAT | V-Guard
Trending Blogs: EPS Formula | DE Ratio | ROE | PB Ratio | Dividend Yield | PE Ratio | Penny Stocks | Demat Account | Fundamentally Strong Penny Stocks | Fundamentally Strong Stocks In BSE | Debt Free Penny Stocks Below 1 Rupee
General
arrow down